Development of regenerative therapy of central nervous system, using with asialo-erythropoietin

已知全身应用大剂量重组人促红细胞生成素(RhEPO)可减轻缺血性损伤。然而，大剂量的重组人促红细胞生成素可能通过增加血液粘度而加重缺血性损害。去唾液红细胞生成素(AsialoEPO)是一种血浆半衰期极短的EPO衍生物，其促红细胞生成作用明显弱于普通EPO。我们试图确定asialo EPO在沙土鼠短暂性前脑缺血模型中是否具有与单纯EPO相同的神经保护作用，由此产生的asialo EPO与EPO一样，可以在不影响红细胞生成的情况下保护海马CA1区神经元免受缺血损伤。提示去唾液酸促红细胞生成素有可能成为未来新型的神经保护剂。

Systemic administration of high-dose recombinant human erythropoietin(rhEPO) is known to attenuate ischemic injury. However, high-dose rhEPO might aggravate ischemic lesions by increasing blood viscosity because of its erythropoietic effects. Asialoerythropoietin(asialoEPO), an EPO derivative with an extremely short plasma half-life, has considerably lesser erythropoietic effect than that of naive EPO. We attempted to determine whether asialoEPO exerts the same neuroprotective effect as naive EPO in a gerbil transient forebrain ischemia model, and resulting multiple dosing of asialoEPO, like EPO, could protect the hippocampal CA1 neurons from ischemic damage without affecting erythropoiesis. This data suggested that asialoEPO would be novel neuro-protective agent in the future.